“Cigarettes belong in museums,” says Philip Morris International CEO in speech in London
23.5.2023 11:10:00 EEST | Business Wire | Press release
Jacek Olczak, Chief Executive Officer of Philip Morris International Inc. (PMI) (NYSE: PM), today delivered remarks at the UnHerd Club in London, calling on governments globally to accelerate the end of cigarettes.
In his remarks to global media, politicians, and policymakers, Olczak shared that “cigarettes belong in museums” but that current policies to reduce smoking prevalence are not working fast enough and may be prolonging smoking.
Drawing upon a new hypothetical model based on World Health Organization data, estimates, and methods, as well as other third party data, Olczak explained that even if smoke-free products were assumed to be only 80 percent less risky than cigarettes, if people who currently smoke were to switch to them completely, then over their lifetime there’s a potential for a tenfold reduction in smoking-attributable deaths compared with historical tobacco control measures alone. He highlighted the absurd paradox that smoke-free products are banned in some countries while cigarettes—despite their far greater risk of harm—can still be sold. While this model has limitations and is built on assumptions, the public health cost of ignoring the potential of smoke-free products could be immense.
In 2016, PMI committed to moving away from cigarettes. The company has invested more than USD 10.5 billion (as of March 31, 2023) since 2008 in developing and commercializing smoke-free products—which today account for nearly 35 percent of the company’s total net revenues. The mission, Olczak explained, is to reduce smoking by replacing cigarettes with less harmful alternatives and ultimately to make cigarettes obsolete. However, PMI’s ability to progress on this mission is being frustrated by a combination of blind opposition from anti-tobacco organizations and governments’ overreliance on the so-called precautionary principle, which some interpret as “better not to do anything until we know everything.”
He called on governments around the world to follow the examples of countries like Sweden and Japan—as well as the U.K.—and adopt policies that give adult smokers who don’t quit a wide choice of alternatives to continuing smoking so they can make better choices and cigarettes can become a historical artifact. He also challenged anti-tobacco organizations to update their thinking, stop blocking innovation, and work toward a common goal to achieve a smoke-free future, faster.
The full speech is available below:
“We’ve all heard the line, ‘Insanity is doing the same thing over and over again and expecting different results.’
And still, despite often restrictive regulations, high product prices, marketing bans, and packaging designed to discourage buying, today public health data show that a billion people worldwide choose to smoke.
Not to mention public health campaigns—and even companies like mine—urging people not to smoke.
The persistence of high smoking rates globally is evidence that the current approach to ending cigarette use is not working quickly enough.
And yet the most common response to the problem is more of the same.
It’s time to try something else. To try a more inclusive and innovative approach; one that has been proven in several countries around the world and that has the potential to significantly accelerate an end to cigarettes.
For adults who would otherwise continue to smoke, switching to a smoke-free product is a pragmatic option that can have a positive impact on both individual and public health.
Let there be no mistake: People who have never used tobacco or nicotine, especially minors, should not use these products. And there’s no doubt that quitting altogether, or better still, never starting, is the best choice.
But, let’s focus for now on adult smokers who have not quit. Today, thanks to smoke-free products, these one billion people have better options than continuing to smoke. And because of these options, we can begin to imagine an accelerated decline in smoking and associated diseases … and not by a little, by a lot.
Here’s the curious thing: I’m moving Philip Morris International out of cigarettes, but the faster I go, the more people shout at me.
Our mission is clear: to reduce smoking by replacing cigarettes with less harmful alternatives.
Cigarettes belong in museums.
Since 2016, my company has fully committed to moving away from cigarettes, the most harmful form of nicotine consumption. We have invested more than 10.5 billion U.S. dollars in developing and commercializing smoke-free products—which today account for nearly 35 percent of our total net revenues.
Our ability to make further progress is being blocked by those who are blindly guided by a desire to see an end to the industry rather than an end to cigarettes. This is very frustrating.
This, together with an overreliance on the so-called precautionary principle—which some interpret as “better not to do anything until we know everything”—results in government inaction and more of the same.
Today’s environment and rhetoric make it easier for governments and regulators to do nothing on smoke-free alternatives. It’s perceived as safer for political careers to abstain from the debate completely rather than be seen as siding with us.
But, in the end, this is just prolonging the life of cigarettes and risks shortening the lives of those who use them.
For smokers today, inaction is not a neutral position. It is a choice with real-world outcomes.
We are entering what Churchill called “a period of consequences.”
It is no longer a case of if these smoke-free alternatives are better than cigarette smoking; it is a case of by how much.
Using the World Health Organization’s data, estimates, and methods, we’ve calculated the potential positive public health impact of the world’s smokers switching from cigarettes to less harmful, smoke-free products.
This hypothetical model shows that if these products are assumed to be 80 percent less risky than cigarettes—and if people who currently smoke were to switch to them completely—then over their lifetime, there’s a potential for a tenfold reduction in smoking-attributable deaths compared with historical tobacco control measures alone.
Let me repeat that hypothesis: Based on the W-H-O’s own data, we see the real potential for a tenfold reduction in smoking-attributable deaths if smokers fully switched to smoke-free products. And this positive impact could be even greater when combined with traditional measures to discourage initiation and encourage cessation.
While there are limitations to this kind of hypothetical analysis, this estimate begins to show the real impact of inaction. The human impact.
But this is not just a hypothetical situation.
Look at public health data in Sweden, a country that today boasts one of the developed world’s lowest smoking rates, at around 5 percent.
There, snus—a non-combustible form of moist tobacco that is placed between the lip and gums—is the most commonly used alternative to cigarettes.
According to this data, mortality rates due to tobacco use in Sweden are much, much lower than in EU countries where snus are banned.
The Swedish Snus Commission estimates that more than 350,000 smoking-attributable deaths among men could have been avoided each year if the other EU countries had matched Sweden’s tobacco-related mortality rate.
We can also look at Japan, which has seen rapidly declining smoking rates since the introduction of heated tobacco products in 2014. Just like in Sweden, these non-combustible products are beginning to replace cigarettes.
Five years after the products were introduced, the Japanese National Health and Nutrition Survey showed an unprecedented decline in the number of adults who smoke cigarettes. More recent studies show that the pace of decline has continued, and today only about 12 percent of Japanese adults smoke. And while more research is needed, we are beginning to see the emergence of encouraging data hinting at a positive impact on public health already.
Contrast this with Japan’s neighbor Singapore, where smoke-free products are banned. In that country, cigarette sales volume has actually increased, and smoking rates are not going down.
Despite all this evidence, the policy of inaction continues in many places—preventing less harmful products from replacing the cigarette.
When governments—and organizations that lobby them—prevent men and women who continue to smoke from accessing less harmful alternatives, and when they perpetuate misinformation about these products, it has a direct correlation to the persistence of smoking.
My question is: Will governments that ban these products or treat them like cigarettes take responsibility for the consequences?
Will society stand up and call out the organizations that are blocking progress?
Or will this insanity persist—leaving us with more of the same and millions of people needlessly continuing to smoke?
It is time for more countries to follow the lead of Sweden, Japan, and other countries such as the U.K.
It’s time for anti-tobacco organizations to stop fighting against us and start fighting for adults who smoke. Just imagine the impact of a potential tenfold further reduction if all current adult smokers were to fully switch for the remainder of their lives to smoke-free products, compared with historical measures alone.
It’s time to work toward a common goal of delivering effective policies that make cigarettes a historical artifact, a museum piece collecting dust behind glass cases.
We need to remember that there is a real, human impact of inaction. Because not taking an evidenced-based decision on smoke-free products today is a decision with consequences.”
ENDS
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration (FDA) has authorized versions of PMI’s IQOS Platform 1 devices and consumables and Swedish Match’s General snus as Modified Risk Tobacco Products (MRTPs). As of March 31, 2023, PMI's smoke-free products were available for sale in 78 markets, and PMI estimates that approximately 18.5 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 35% of PMI’s total 2023 first-quarter net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.
Forward-Looking and Cautionary Statements
This press release contains projections of future results and goals and other forward-looking statements, including statements regarding the impact of smoke-free products, as well as operational plans and strategies. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI.
PMI's business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; the impact of COVID-19 on PMI's business; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful in its attempts to produce and commercialize reduced-risk products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; if it is unable to attract and retain the best global talent, including women or diverse candidates; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our reduced-risk product category's performance.
PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022 and the Form 10-Q for the quarter ended March 31, 2023. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005595/en/
Contact information
Philip Morris International
David Fraser
T. +41 (0)58 242 4500
E. david.fraser@pmi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Completes Acquisition of PEAK:AIO to Accelerate Zettabyte-scale AI Deployments2.11.2026 15:00:00 EET | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it completed the acquisition of PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. With this acquisition, NetApp can leverage metadata services and parallel namespace innovations to power the fastest storage on the planet, NetApp Novus, to support zettabyte-scale file systems for the most demanding workloads of AI clouds and GPU-as-a-service providers. For the best AI infrastructure economics, organizations need to keep GPU resources continuously supplied with data without bottlenecks. The acquisition advances NetApp’s strategy for the next phase of AI infrastructure by bringing PEAK:AIO’s metadata and parallel file system expertise together with NetApp ONTAP, giving customers a path to AI-scale storage that combines high concurrency and massive namespace growth with the resilience, security, and operational simplicity enterprises already trust
HistoSonics Receives Regulatory Approval in Singapore, Advancing Expansion Across Asia-Pacific2.11.2026 15:00:00 EET | Press release
HistoSonics today announced that the company has received market authorization from Singapore’s Health Sciences Authority (HSA) for its Edison® Histotripsy System (under the device name HistoSonics Histotripsy System), marking another significant milestone in the company’s continued international expansion and creating new opportunities to advance access to histotripsy throughout the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102090757/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image-guided platform that uses the mechanical properties of focused ultrasound, known as histotripsy, to mechanically destroy and liquefy unwanted tissue and tumors. The technology offers a fundamentally new approach to tissue destruction without the need for invasive procedures, radiation, or thermal energy. The Edison System is currently authorized for the destruction of liver
Bentley Systems Announces Seequent’s Acquisition of Seismic Interpretation Software Company Eliis2.11.2026 15:00:00 EET | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that Seequent, The Bentley Subsurface Company, has acquired seismic interpretation software company Eliis. The acquisition will enrich Seequent’s capabilities in geophysics with seismic data interpretation and further advance subsurface understanding to help solve complex global challenges. Eliis’ global team of more than 100 geoscientists, technical specialists, and researchers will join Seequent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029964674/en/ 3D view from PaleoScan showcasing recent advancements in seismic interpretation workflows that support prospect evaluation and exploration decision-making Founded in 2007 and with headquarters in Montpellier, France, Eliis develops advanced seismic interpretation software that helps geoscientists process and analyze seismic imaging data to build detailed model
NIQ Publishes 2026 ESG Progress Report, Highlighting Action Across Climate, People, Communities, and Responsible AI2.11.2026 13:45:00 EET | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2026 Environmental, Social and Governance (ESG) Progress Report, detailing the company’s progress on key ESG priorities throughout 2025. The report covers NIQ’s efforts across environmental responsibility, its people and communities, data integrity, and responsible AI. Key highlights from 2025 include: Strengthened its approach to climate risk and environmental measurement: NIQ conducted its first climate risk assessment aligned with Task Force on Climate-related Financial Disclosures (TCFD) recommendations, tracked Scope 1, 2 and 3 emissions under the GHG Protocol, and externally verified its carbon footprint. Invested in associate development, engagement and well-being: Internal mobility increased to 35%, up from 30%, while performance review completion reached 99% and the employee survey response rate reached 89%. NIQ also introduced three new leadership development tracks, while Employee Assistance Program
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer2.11.2026 13:42:00 EET | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable, locally advanced colon cancer. The manuscript, titled “Preoperative botensilimab with or without balstilimab for patients with resectable, locally advanced pMMR or dMMR colon cancer: the UNICORN trial by GONO,” was published in Nature Medicine and is available at DOI 10.1038/s41591-026-04710-1. The UNICORN trial enrolled 56 patients in four non-randomized cohorts of 14, evaluating BOT alone or BOT+BAL in mismatch repair proficient/microsatellite stable (pMMR/MSS) and mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) colon cancer. The study ass
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
